Tecvayli

Advertisement

cGxPJobs Banner

Johnson & Johnson Expands TECVAYLI for Multiple Myeloma Care

Beerse, Belgium, August 21, 2026 Johnson & Johnson announced that the European Commission (EC) has approved an indication extension...

By cGxPwire Editor
August 23, 2026

Read More

Johnson & Johnson Advances Myeloma Care with TECVAYLI and TALVEY

RARITAN, N.J., July 23, 2026 Johnson & Johnson has announced positive topline results from the Phase 3 MonumenTAL-6 clinical...

By cGxPwire Editor
July 25, 2026

Read More

Johnson & Johnson Submits TECVAYLI EMA Application

Beerse, Belgium — March 10, 2026 Global healthcare company Johnson & Johnson has announced the submission of a Type...

By cGxPwire Editor
March 11, 2026

Read More

Johnson & Johnson Wins FDA Approval for Tecvayli–Darzalex Myeloma Therapy

HORSHAM, Pennsylvania – March 5, 2026 Johnson & Johnson announced that the U.S. Food and Drug Administration has approved...

By cGxPwire Editor
March 6, 2026

Read More

Advertisement

cGxPJobs

Directory